Crossmark

Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response

Crossref DOI link: https://doi.org/10.1186/s12943-025-02314-w

Published Online: 2025-04-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zeng, Fanhong

Zhang, Qingyang

Tsui, Yu-Man

Ma, Huanhuan

Tian, Lu

Husain, Abdullah

Lu, Jingyi

Lee, Joyce Man-Fong

Zhang, Vanilla Xin

Li, Po-Man

Cheung, Gary Cheuk-Hang

Cheung, Tan-To

Ho, Daniel Wai-Hung

Ng, Irene Oi-Lin
License Information

Text and Data Mining valid from 2025-04-09

Version of Record valid from 2025-04-09
More Information

Article History

Received: 15 October 2024

Accepted: 25 March 2025

First Online: 9 April 2025

Declarations

:

: All human experiments were approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW 17–056). The animal experiment was approved by the Committee on the Use of Live Animals in Teaching and Research (CULATR 5688–21), Li Ka Shing Faculty of Medicine, University of Hong Kong.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below